CAS 1257044-40-8

ABT-199

Description:

ABT-199, also known as Venetoclax, is a small molecule inhibitor primarily designed to target the B-cell lymphoma 2 (BCL-2) protein, which plays a crucial role in regulating apoptosis (programmed cell death). This compound is characterized by its ability to selectively bind to BCL-2, thereby promoting the apoptosis of cancer cells that overexpress this protein, particularly in certain types of hematological malignancies such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). ABT-199 exhibits a high degree of specificity for BCL-2 over other BCL-2 family proteins, which contributes to its therapeutic efficacy and safety profile. The substance is administered orally and has been associated with various side effects, including neutropenia and tumor lysis syndrome, necessitating careful monitoring during treatment. Its development marked a significant advancement in targeted cancer therapies, providing a novel approach to treating malignancies that are resistant to conventional therapies. Overall, ABT-199 represents a critical advancement in the field of oncology, particularly for patients with specific BCL-2-dependent cancers.

Formula: C₄₅H₅₀ClN₇O₇S

InChI: InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)

InChI key: InChIKey=LQBVNQSMGBZMKD-UHFFFAOYSA-N

SMILES: C(C1=C(CC(C)(C)CC1)C2=CC=C(Cl)C=C2)N3CCN(CC3)C4=CC(OC=5C=C6C(=NC5)NC=C6)=C(C(NS(=O)(=O)C7=CC(N(=O)=O)=C(NCC8CCOCC8)C=C7)=O)C=C4

Synonyms:

• 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide
• Benzamide, 4-[4-[[2-(4-chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-
• Gdc-0199
• Rg 7601
• Rg7601
• Venclexta
• Venclyxto
• Venetoclax
• ABT 199
• 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-((tetrahydro-2H-pyran-4-yl)methylamino)phenylsulfonyl)benzamide
• GDC0199
• ABT199,GDC0199
• 4-[4-[[2-(4-Chlorophenyl)-4,4-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[3-nitro-4-[[(tetrahydro-2H-pyran-4-yl)methyl]amino]phenyl]sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-benzamide ABT-199 (GDC-0199)

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(oxan-4-ylmethyl)amino]benzene}sulfonyl)-2-{1H-pyrrolo[2,3-b]pyridin-5-yloxy}benzamide

CAS: 1257044-40-8

Formula: C₄₅H₅₀ClN₇O₇S

Purity: 99%

Color and Shape: Solid

Molecular weight: 868.4392

Ref: IN-DA000OIU

Venetoclax

CAS: 1257044-40-8

Formula: C₄₅H₅₀ClN₇O₇S

Color and Shape: Yellow Solid

Molecular weight: 868.45

Ref: 4Z-V-064001

Venetoclax

CAS: 1257044-40-8

Venetoclax

Purity: ≥98%

Molecular weight: 868.44g/mol

Ref: 54-BUP16820

Venetoclax-d8 (piperazine-d8)

CAS: 1257044-40-8, 1257051-06-1

Purity: 98 atom % D

Molecular weight: 875.36

Ref: 3U-D8267

Venetoclax

CAS: 1257044-40-8

Venetoclax (ABT-199) is a selective inhibitor of Bcl-2 (Ki < 0.010 nM), binding over 3 orders of magnitude less avidly to Bcl-xL, and Bcl-W (Kis = 48/245 nM).

Formula: C₄₅H₅₀ClN₇O₇S

Purity: 98.00% - 99.97%

Color and Shape: Solid

Molecular weight: 868.44

Ref: TM-T2119

Venetoclax

CAS: 1257044-40-8

Formula: C₄₅H₅₀ClN₇O₇S

Molecular weight: 868.45

Ref: ST-EA-CP-V17000

ABT 199 (>99%)(Venetoclax)

Controlled Product

CAS: 1257044-40-8

Applications ABT 199 (>99%) is a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
References Davids, M. & Letai, A.: Cancer Cell, 23, 139 (2013); Souers, A.,et al.: Nat. Med., 19, 202 (2013); Vaillant, F., et al.: Cancer Cell, 24, 120 (2013); Vogler, M., et al.: Brit. J. Haematol., 163, 139 (2013);

Formula: C₄₅H₅₀ClN₇O₇S

Color and Shape: Light Yellow To Yellow

Molecular weight: 868.44

Ref: TR-A112425

ABT 199 (Venetoclax)

Controlled Product

CAS: 1257044-40-8

Applications ABT 199 is a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
References Davids, M. & Letai, A.: Cancer Cell, 23, 139 (2013); Souers, A.,et al.: Nat. Med., 19, 202 (2013); Vaillant, F., et al.: Cancer Cell, 24, 120 (2013); Vogler, M., et al.: Brit. J. Haematol., 163, 139 (2013);

Formula: C₄₅H₅₀ClN₇O₇S

Color and Shape: Light Yellow To Yellow

Molecular weight: 868.44

Ref: TR-A112430

Venetoclax

CAS: 1257044-40-8

A BCL-2 selective inhibitor with no effect on Bcl-xl and thereby prevents thrombocytopenia. Increased sensitivity observed in Bcl-2-dependent haematological tumour cell lines. Elicits additional benefits to tamoxifen treatment in ER-positive breast cancer xenografts.

Formula: C₄₅H₅₀ClN₇O₇S

Purity: Min. 98 Area-%

Color and Shape: Yellow Powder

Molecular weight: 868.44 g/mol

Ref: 3D-FV63222

ABT-199-D10

Controlled Product

CAS: 1257044-40-8

Applications ABT-199-D10 is a deuterized form of ABT 199 (A112430), which is a potent and selective BCL-2 inhibitor that achieves potent antitumor activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.
References Davids, M. & Letai, A.: Cancer Cell, 23, 139 (2013); Souers, A.,et al.: Nat. Med., 19, 202 (2013); Vaillant, F., et al.: Cancer Cell, 24, 120 (2013); Vogler, M., et al.: Brit. J. Haematol., 163, 139 (2013);

Formula: C₄₅D₁₀H₄₀ClN₇O₇S

Color and Shape: Neat

Molecular weight: 878.5

Ref: TR-A112432